课题基金 / 基金详情

ATM mutations in breas cancer - a functional approach

ATM mutations in breas cancer - a functional approach
乳腺癌中的 ATM 突变——一种功能性方法
批准号:
7500539
负责人:
Patrick Concannon
金额:
$14.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-01 至 2009-05-31

项目摘要

项目成果

Patrick Concannon的其他基金

相似基金

相关文献

中文摘要
翻译
电离辐射(IR)是一种在动物和人类中都已知的乳腺癌致癌物质。红外线暴露会产生各种不同的 DNA损伤中最危险的是DNA双链断裂(DSB)。基因组不稳定可能导致 由于未修复的DSB的存在导致细胞死亡或恶性转化。真核生物已经进化 用于监测基因组完整性并通过细胞周期停滞、修复、 和/或凋亡机制。哺乳动物细胞DNA DSB反应途径的主要调节因子是 蛋白质ATM机。ATM是这一途径中的几种蛋白质之一,这些蛋白质由与乳腺癌有关的基因编码 敏感度。尽管IR、乳腺癌和这些基因之间的关系很有趣,但目前还没有明确的模型 这种特殊的生化途径是如何对乳腺癌风险产生特定影响的。我们现在已经开发了一个模型,用于 自动取款机的角色。在这个“错义突变”模型中,我们提出ATM突变的一个子集通过显性作用 干扰,降低ATM的内在激酶活性,和/或破坏包括ATM的蛋白质复合体。这个 模型预测ATM介导的乳腺癌风险仅限于这类突变的携带者,并建议 像IR这样的试剂是ATM的有效诱导剂,可能会增强这些人的致癌作用。 为了探索ATM、辐射暴露与乳腺癌之间的复杂关系,我们发起了 WeCare(女性环境癌症和辐射暴露)研究中,2100名患有单边癌症和辐射的女性 或非同步双侧乳腺癌入选。在这个集合中,乳腺癌风险因素已经通过 问卷;ATM基因的全辐射剂量重建和全突变筛查均已完成 被执行。对ATM数据的初步分析显示,患第二乳房的风险显著增加 接受放射治疗并携带ATM错义突变的受试者中的癌症。然而,突变状态 仅基于序列保守性的考虑,没有突变的功能确认 地位包括在最初的研究中。在这一新的应用中,我们建议建立在这些初步发现的基础上 通过直接检验以下假设,即在符合以下条件的女性中,对侧乳腺癌的发病率增加 接受放射治疗作为第一次原发性乳腺癌的治疗,这些人是特定ATM的携带者 主要干扰细胞对IR反应的等位基因。我们的研究将描述推定的ATM WeCare筛选过程中发现的突变对DNA损伤反应的功能影响 路径,然后将这些信息纳入整个WeCare研究的变量分析中。
英文摘要
Ionizing radiation (IR) is a known breast carcinogen in both animals and humans. IR exposure generates a variety of lesions in DNA of which the most dangerous are DNA double strand breaks (DSBs). Genomic instability can result from the presence of unrepaired DSBs leading to cell death or malignant transformation. Eukaryotes have evolved efficient systems for monitoring genomic integrity and responding rapidly to their presence via cell cycle arrest, repair, and/or apoptotic mechanisms. The master regulator of the mammalian cellular DNA DSB response pathway is the protein ATM. ATM is one of several proteins in this pathway encoded by genes implicated in breast cancer susceptibility. Despite the intriguing relationship between IR, breast cancer, and these genes, there is no clear model for how this particular biochemical pathway has specific effects on breast cancer risk. We have now developed a model for the role of ATM. In this "missense-mutation" model we propose that a subset of ATM mutations act by dominant interference, reducing the intrinsic kinase activity of ATM, and/or disruptingprotein complexes that includeATM. The model predicts that ATM-mediated risk for breast cancer is specific to carriers of this class of mutation and suggests that agents such as IR, which are potent inducers of ATM, may have enhanced carcinogenic effects in such individuals. In order to explore the complex relationship between ATM, radiation exposure and breast cancer, we initiated the WECARE (Women's Environment Cancer And Radiation Exposure) study in which 2100 women with either unilateral or asynchronous bilateral breast cancer are enrolled. In this collection, breast cancer risk factors have been assessed by questionnaire; both full radiation dosimetry reconstruction, and full mutation screening of the ATMgene have been carried out. Preliminary analysis of the ATM data reveals a significant increase in risk for second primary breast cancers in subjects who received radiation therapy and carry ATM missense mutations. However, mutation status determination was based only on consideration of sequence conservationno functional confirmation ofmutation status was included in the original study. In this new application, we propose to build upon these preliminary findings by directly testing the hypothesis that the incidence of contralateral breast cancer is increased among women who received radiation therapy as a treatment for their first primary breast cancer and who are carriers of specific ATM alleles which dominantly interfere with the cellular response to IR. Our studies will characterize putative ATM mutations identified in the course of WECARE screening for their functional effects on DNA damage response pathways, and then incorporate this information into the analysis of variables for the overall WECARE study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel DNA damage response gene from genomic screening
  • 批准号:
    9324064
  • 项目类别:
  • 资助金额:
    $32.27万
  • 财政年份:
    2016
  • 负责人:
    Patrick Concannon
  • 依托单位:
Novel DNA damage response gene from genomic screening
  • 批准号:
    9158855
  • 项目类别:
  • 资助金额:
    $32.9万
  • 财政年份:
    2016
  • 负责人:
    Patrick Concannon
  • 依托单位:
Novel T1D risk variants from genomic analyses in high risk families
  • 批准号:
    9100744
  • 项目类别:
  • 资助金额:
    $33.75万
  • 财政年份:
    2015
  • 负责人:
    Patrick Concannon
  • 依托单位:
Novel T1D risk variants from genomic analyses in high risk families
  • 批准号:
    8955744
  • 项目类别:
  • 资助金额:
    $33.75万
  • 财政年份:
    2015
  • 负责人:
    Patrick Concannon
  • 依托单位:
海外基金